Bionor appoints Vice President for Investor Relations and Communications

(Oslo, Norway, 12 May 2015) Bionor Pharma ASA (OSE:BIONOR), a peptide vaccine company advancing the potential first therapeutic vaccine towards a functional cure for HIV, today announces the appointment of Jørgen Fischer Ravn as Vice President for Investor Relations and Communications. Jørgen will join the company 1 June 2015.

Jørgen has almost 20 years’ combined experience in healthcare and investor relations both in-house and as a consultant. He joins from Impact Partners, a Danish advisory firm specialized in financial communications, in which he was a Partner, and has previously been Head of Investor Relations at Coloplast A/S. Jørgen has an MSc in Political Science from the University of Aarhus, Denmark.

Bionor’s President and Chief Executive Officer, Dr. David H. Solomon, commented: “Jørgen has significant experience in IR and communications and we welcome him to our newly strengthened team as we pursue our goal to internationalize Bionor’s profile and shareholder base in line with business strategy.”

Jørgen Fischer Ravn added: “I am excited by this opportunity to show how high quality communication can contribute to the long-term success of Bionor. Especially, I look forward to the dialogue with existing and potential investors and other stakeholders about Bionor’s pioneering work to develop a functional cure for HIV.”

Notes for Editors

About Bionor
Bionor Pharma is a leading biotechnology company advancing the first therapeutic vaccine towards a functional cure for HIV. The company’s focus is the research and development of peptide-based vaccines against viral diseases, primarily HIV.

Bionor Pharma’s current clinical development pipeline comprises two vaccine candidates for the treatment of HIV, Vacc-4x and Vacc-C5. Vacc-4x is the most advanced therapeutic vaccine in the HIV space and has demonstrated a reduction of viral load in a large, randomized, controlled Phase II trial, as well as safety and tolerability. Bionor Pharma’s current clinical focus is to explore whether Vacc-4x, used with other medicines as a combination therapy, can reduce the viral load even further, and the company, through a collaboration with Celgene Corp, is investigating Vacc-4x and romidepsin in the REDUC study.

Bionor is listed on the Oslo stock exchange, under the ticker BIONOR.

More information about Bionor is available at www.bionorpharma.com.

For more information please contact:
Bionor Pharma ASA
President and Chief Executive Officer David Solomon: Tel + 45 22 20 63 00

Consilium Strategic Communications
Mary-Jane Elliott / Ivar Milligan / Jessica Hodgson / Hendrik Thys
bionor@consilium-comms.com+44 (0)20 3709 5700